Vasoplegic Syndrome and Noncatecholamine Therapies (StatPearls review chapter) (2024)

Peer-Reviewed Study · Heidi Heyman; Ricardo Serrano (StatPearls Publishing) · January 11, 2024

Heidi Heyman et al., 2024-01-11: Current practice chapter on vasoplegic syndrome placing methylene blue among the non-catecholamine therapies used when catecholamines fail, with mortality up to 25%.

other therapies such as vasopressin, methylene blue, hydroxocobalamin, angiotensin II, and ascorbic acid have all demonstrated benefits

Heidi Heyman et al., 2024-01-11: Current practice chapter on vasoplegic syndrome placing methylene blue among the non-catecholamine therapies used when catecholamines fail, with mortality up to 25%. C5 (guidance layer). Study type: narrative review / continuing-education chapter, no patients. Reports incidence 5-25% in the cardiac literature and mortality as high as 25%; states catecholamines remain the mainstay and lists vasopressin, methylene blue, hydroxocobalamin, angiotensin II and ascorbic acid as adjuncts with demonstrated benefit. No methylene-blue dose given in the excerpt captured. Disclosures: Heidi Heyman and Ricardo Serrano declare no relevant financial relationships with ineligible companies. Quote verified against the Bookshelf HTML read through the web_extract route (plain HTTP returns a reCAPTCHA stub). Added after the main pass; see run notes. Study type: review.